Prevalence and impact on FEV 1 decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with Cystic Fibrosis. A single-center, case control study of 165 patients

Journal of Cystic Fibrosis

Volumn 11, Issue 1, 2012, Pages 2-7

  Vanderhelst, E ^a   De Meirleir, L ^a   Verbanck, S ^a   Pierard D ^a   Vincken, W ^a   Malfroot, A ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Bronchiectasis; Cystic fibrosis disease progression; FEV1 decline; MRSA infection

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BRONCHIECTASIS; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; GENE DELETION; GENOTYPE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PANCREAS; PRESCHOOL CHILD; PREVALENCE; SCHOOL CHILD; SPIROMETRY;

ADOLESCENT; ADULT; BRONCHIECTASIS; CASE-CONTROL STUDIES; CYSTIC FIBROSIS; DISEASE PROGRESSION; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SPIROMETRY; STAPHYLOCOCCAL INFECTIONS; YOUNG ADULT;

EID: 84855904138     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.08.006     Document Type: Article

References (21)

1. Rosenstein B.J., Zeitlin P.L. Cystic fibrosis. Lancet 1998, 351:277-282.
2. Boxerbaum B., Jacobs M.R., Cechner R.L. Prevalence and significance of methicilin-resistant Staphylococcus aureus in patients with cystic fibrosis. Pediatr Pulm 1988, 4:159-163.
3. Miall L.S., McGinley N.T., Brownlee K.G., Conway S.P. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child 2001, 84:160-162.
4. Goodrich J., Sutton-Shields T.N., Kerr A., Wedd J.P., Miller M.B., Gilligan P.H. Prevalence of community-associated methicillin-resistant Staphyloccus aureus in patients with cystic fibrosis. J Clin Microbiol 2009, 47:1231-1233.
5. Giron R.M., Buendia B., Pinedo C., Casanova A., Hoyos N., Ancochea J. Methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. Enferm Infecc Microbiol Clin 2009, 27:85-88.
6. Ren C., Morgan W.J., Konstan M.W., Schechter M.S., Wagener J.S., Fisher K.A., et al. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulm 2007, 42:513-518.
7. Annual report from the Cystic Fibrosis Foundation 2008.
8. Spicuzza L., Sciuto C., Vitaliti G., Di Dio G., Leonardi S., La Rosa M. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur J Clin Microbiol Infect Dis 2009, 28(2):191-195.
9. Steinkamp G., Wiedemann B., Rietschel E., Krahl A., Gielen J., Bärmeier H., et al. Prospective evaluation of emerging bacteria in cystic fibrosis. J Cyst Fibrosis 2005, 4(1):41-48.
10. Vergison A., Denis O., Deplano A., Casimir G., Claeys G., DeBaets F., et al. National survey of molecular epidemiology of Staphylococcus aureus colonization in Belgian cystic fibrosis patients. J Antimicrob Chemother 2007, 59(5):893-899.
11. Dasenbrook E., Checkley W., Merlo C., Konstan M., Lechtzin N., Boyle M. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. J Am Med Assoc 2010, 303:2386-2392.
12. Dasenbrook E., Merlo C., Diener-West M., Lechtzin N., Boyle M. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:814-821.
13. Boyle M.P., Ross T., Goldberg J.D. Molecular epidemiology of MRSA infection in cystic fibrosis and its clinical implications. Pediatr Pulm 2005, 28:288-289.
14. Thomas S.R., Gyi K.M., Gaya H., Hudson M.E. Methicillin-resistant Staphylococcus aureus - impact at a national cystic fibrosis centre. J Hosp Infect 1998, 40:203-209.
15. Nadeslingam K., Conway S., Denton M. Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis. J Cyst Fibros 2005, 4:49-52.
16. Stefani S., Varldo P.E. Epidemiology of methicillin-resistant staphylococci in Europe. Clin Microbiol Infect 2003, 9:1179-1186.
17. Glikman D., Siegel J., David M., Okoro N., Boyle-Vara S., Doweel M., et al. Complex molecular epidemiology of methicillin-resistant Staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S. aureus. Chest 2008, 133:1381-1387.
18. Elizur A., Orscheln R., Ferkol T., Atkinson J., Dunne W., Buller R., et al. Panton-Valentine Leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Chest 2007, 131:1718-1725.
19. Kerem E., Corey M., Kerem B.S., Rommens J., Markiewicz D., Levison H., et al. The relation between genotype and phenotype in cystic fibrosis-analysis of the most common mutation (δF508). N Engl J Med 1990, 323:1517-1522.
20. Milla C.E., Warwick W.J. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 1998, 113:1230-1234.
21. Doe S.J., McSorley A., Isalka B., Kearns A.M., Bright-Thomas R., Brennan A.L., et al. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros 2010, 9:104-109.